Learning Objectives
Following the completion of this activity, participants should be able to:
- Develop a plan to increase proactive screening and diagnosis of Alzheimer's disease within the limitations of a busy primary care practice or geriatric setting
- Describe risk factors for the development of Alzheimer's disease
- Apply diagnostic criteria for Alzheimer's disease to typical patient types
- Review current and new therapeutic strategies for patients with different stages of Alzheimer's disease
- Describe the neuropsychiatric features of Alzheimer's disease and specific treatment recommendations
- Describe the health-related risk and effective interventions to improve the mental and physical well-being of patients and their families and caregivers
Target Audience
This educational activity is designed for practicing primary care physicians, nurse practitioners, physician assistants, and other health care professionals who are involved with the diagnosis, treatment, and management of patients with Alzheimer's disease.
Accreditation Statement
Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
Certification Statement
Temple University School of Medicine designates this educational activity for a maximum of 1.5 AMA Physician's Recognition Award Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure Policy
It is the policy of Temple University School of Medicine, The Albert J. Finestone, M.D., Office of Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s). The Temple CME department is responsible for resolving conflicts of interest.
The information presented at this CME program represents the views and opinions of the individual presenters and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System, or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including, without limitation, FDA-approved uses and any off-label uses.
Faculty Disclosure Declarations
J. Wesson Ashford Jr, MD, PhD, has been a consultant for Medivation, Inc.; Orasi Medical, Inc.; and Pfizer Inc. He is a shareholder of Bowles-Langley Technology, Inc. and Satoris, Inc.
P. Murali Doraiswamy, MD, has been a consultant for Accera, Inc.; Avid Radiopharmaceuticals, Inc.; Cortex Pharmaceuticals, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; Medivation, Inc.; Myriad Pharmaceuticals, Inc.; and Schering-Plough Corporation. He has received grant/research support from Avid Radiopharmaceuticals, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Medivation, Inc.; Myriad Pharmaceuticals, Inc.; and sanofi-aventis. He is a member of the speakers bureaus for Forest Laboratories, Inc. and Otsuka America Pharmaceutical, Inc. He is a stockholder of Sonexa Therapeutics, Inc.
Elaine R. Peskind, MD, has been a consultant for Forest Laboratories, Inc. and Novartis Pharmaceuticals Corporation. She has received grant/research support from Elan Pharmaceuticals, Inc. She is a member of the speakers bureaus for Forest Laboratories, Inc. and Novartis Pharmaceuticals Corporation. She is a stockholder for Elan Pharmaceuticals, Inc.
Pierre N. Tariot, MD, has been a consultant for Abbott Laboratories; Acadia Pharmaceuticals Inc.; AC Immune SA; AstraZeneca Pharmaceuticals LP; Avid Radiopharmaceuticals, Inc.; Baxter International Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EPIX Pharmaceuticals, Inc.; Forest Laboratories, Inc.; GlaxoSmithKline; Medivation, Inc.; Memory Pharmaceuticals Corp.; Merck & Co., Inc.; Myriad Pharmaceuticals, Inc.; Pfizer Inc.; sanofi-aventis; Schering-Plough Corporation; Takeda Pharmaceutical Company Limited; Toyama Chemical Co., Ltd.; Worldwide Clinical Trials, Inc.; and Wyeth Pharmaceuticals Inc. He has recieved grant/research support from Abbott Laboratories; Alzheimer's Association; Arizona Department of Health Services; AstraZeneca Pharmaceuticals LP; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Institute for Mental Health Research; Medivation, Inc.; Merck & Co., Inc.; National Institute of Mental Health; National Institute on Aging; Pfizer Inc.; Takeda Pharmaceutical Company Limited; and Wyeth Pharmaceuticals Inc.
All conflicts were resolved.
Planning Committee Disclosures
Members of Temple University School of Medicine, the Alzheimer's Foundation of America, and HealthcareFirst have no commercial relationships to disclose.